Biotech Values

[urche]

Turnaround for 2008

I would support CAMH, Response, Javelin, Momenta as beaten down and poised for major movement depending on outcome of near term events. In the case of Momenta, there is a collar (cash) that should prevent it being a worst of 2008 contender. Spectrum wouldn't go on my list just because it has enough in its pipeline to keep it away from the best or worst ends of the scale.

Although it probably only has about 5 private shareholders left (including Randy and I), Cobalis may also qualify. At 6 cents per share, it is more likely to be zero or a buck at the end of the year than anywhere in between. CBLS, BTW, had the distinction of adding the letter "e" to its ticker this week.